[开放获取]    关注儿童猴痘易感性的现状、挑战与应对

doi:10.35541/cjd.20250170

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (10): 910-913.doi: 10.35541/cjd.20250170

• 专题笔谈·儿童皮肤病 • 上一篇下一篇

[开放获取] 关注儿童猴痘易感性的现状、挑战与应对

卢清华¹ 禹定乐¹ 马香^2，3 殷俊³ 马琳⁴ 杨永弘^5，6

¹深圳市儿童医院呼吸科，深圳 518038；²山东大学附属儿童医院济南市儿童医院儿科研究所呼吸科，济南 250022；³安徽医科大学第一附属医院感染科/医院感染管理科，合肥 230022；⁴首都医科大学附属北京儿童医院皮肤科，北京 100045；⁵安徽医科大学附属第一医院儿科，合肥 230022；⁶首都医科大学附属北京儿童医院微生物免疫室，北京 100045

收稿日期:2025-04-01 修回日期:2025-07-18 发布日期:2025-09-30
通讯作者: 杨永弘 E-mail:yyh628628@sina.com

Focusing on the status, challenges and countermeasures of mpox susceptibility in children

Lu Qinghua¹, Yu Dingle¹, Ma Xiang^2,3, Yin Jun³, Ma Lin⁴, Yang Yonghong^5,6

¹Department of Respiratory Medicine, Shenzhen Children′s Hospital, Shenzhen 518038, Guangdong, China; ²Department of Respiratory Medicine, Children's Hospital Affiliated to Shandong University, Pediatric Research Institute, Jinan Children's Hospital, Jinan 250022, China; ³Department of Infectious Diseases/Nosocomial Infection Management, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China; ⁴Department of Dermatology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; ⁵Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China; ⁶Department of Microbiology and Immunology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China

Received:2025-04-01 Revised:2025-07-18 Published:2025-09-30
Contact: Yang Yonghong E-mail:yyh628628@sina.com

摘要/Abstract

摘要： 【摘要】猴痘疫情自2022年全球暴发以来，已从非洲地方性流行演变为国际关注的突发公共卫生事件。2024年刚果民主共和国发生由Clade Ⅰb分支引发的猴痘疫情再次敲响警钟，15岁以下儿童患病率及致死率均显著升高，儿童群体面临新的挑战。因此需要加强防控，阻断母婴传播途径，建立社区积极参与的创新模式，降低猴痘发生风险。未来亟需研究病毒母婴传播的分子机制，开发靶向抗病毒药物，建立儿童重症评分系统，将猴痘疫苗纳入世界卫生组织扩大免疫规划。

关键词: 猴痘, 儿童, 体征和症状, 治疗, 传染病控制

Abstract: 【Abstract】 Since the global outbreak in 2022, the mpox epidemic has evolved from an African endemic to a public health emergency of international concern. The 2024 mpox outbreak in the Democratic Republic of the Congo caused by the Clade Ⅰb lineage is yet another wake?up call, with markedly higher prevalence and fatality rates observed among children under 15 years of age, thereby presenting new challenges for the children. Therefore, it is necessary to strengthen prevention and control, block mother?to?child transmission routes, and establish innovative models with active community participation to reduce the risk of mpox transmission. In the future, it is urgent to analyze molecular mechanisms underlying the mother?to?child transmission of the virus, develop targeted antiviral drugs, establish a pediatric critical disease scoring system, and incorporate mpox vaccines into the World Health Organization′s expanded programme on immunization.

Key words: Monkeypox, Child, Signs and symptoms, Therapy, Communicable disease control

卢清华禹定乐马香, 殷俊马琳杨永弘, . [开放获取] 关注儿童猴痘易感性的现状、挑战与应对[J]. 中华皮肤科杂志, 2025,58(10):910-913. doi:10.35541/cjd.20250170

Lu Qinghua, Yu Dingle, Ma Xiang, Yin Jun, Ma Lin, Yang Yonghong, . Focusing on the status, challenges and countermeasures of mpox susceptibility in children[J]. Chinese Journal of Dermatology, 2025, 58(10): 910-913.doi:10.35541/cjd.20250170

参考文献 26

［1］	Krasemann S, Fodjo J, Mohamed O, et al. Public health priorities for mpox clade Ⅰb in pregnant, breastfeeding, and paediatric populations in DR Congo［J］. Lancet Infect Dis, 2025,25（4）:372⁃374. doi: 10.1016/S1473⁃3099（25）00152⁃5.
［2］	Katoto PD, Muttamba W, Bahizire E, et al. Shifting transmission patterns of human mpox in South Kivu, DR Congo［J］. Lancet Infect Dis, 2024,24（6）:e354⁃e355. doi: 10.1016/S1473⁃3099（24）00287⁃1.
［3］	World Health Organization （WHO）. Multi⁃country monkeypox outbreak: situation update［EB/OL］. （2022⁃06⁃27）［2025⁃07⁃20］. https://www.who.int/emergencies/disease⁃outbreak⁃news/item/2022⁃DON396.
［4］	Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox virus infection in humans across 16 countries ⁃ April⁃June 2022［J］. N Engl J Med, 2022,387（8）:679⁃691. doi: 10.1056/NEJMoa2207323.
［5］	Sers R. Humanitarian and health⁃care crises in eastern DR Congo［J］. Lancet, 2025,405（10478）:532⁃533. doi: 10.1016/S0140⁃6736（25）00290⁃9.
［6］	World Health Organization. Mpox⁃Democratic Republic of the Congo［EB/OL］. （2024⁃06⁃14）［2025⁃07⁃20］. https://www.who.int/emergencies/disease⁃outbreak⁃news/item/2024⁃DON522.
［7］	Schwartz DA, Pittman PR. Mpox （monkeypox） in pregnancy: viral clade differences and their associations with varying obstetrical and fetal outcomes［J］. Viruses, 2023,15（8）:1649. doi: 10.3390/v15081649.
［8］	Nachega JB, Mohr EL, Dashraath P, et al. Mpox in pregnancy ⁃ risks, vertical transmission, prevention, and treatment［J］. N Engl J Med, 2024,391（14）:1267⁃1270. doi: 10.1056/NEJMp 2410045.
［9］	Brosius I, Vakaniaki EH, Mukari G, et al. Epidemiological and clinical features of mpox during the clade Ⅰb outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study［J］. Lancet, 2025,405（10478）:547⁃559. doi: 10.1016/S0140⁃6736（25）00047⁃9.
［10］	Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a global case series［J］. Lancet, 2023,401（10380）:939⁃949. doi: 10.1016/S0140⁃6736（23）00273⁃8.
［11］	Ogoina D, Iroezindu M, James HI, et al. Clinical course and outcome of human monkeypox in Nigeria［J］. Clin Infect Dis, 2020,71（8）:e210⁃e214. doi: 10.1093/cid/ciaa143.
［12］	Huhn GD, Bauer AM, Yorita K, et al. Clinical characteristics of human monkeypox, and risk factors for severe disease［J］. Clin Infect Dis, 2005,41（12）:1742⁃1751. doi: 10.1086/498115.
［13］	Cuérel A, Favre G, Vouga M, et al. Monkeypox and pregnancy: latest updates［J］. Viruses, 2022,14（11）:2520. doi: 10.3390/v14112520.
［14］	Schwartz DA, Mbala⁃Kingebeni P, Patterson K, et al. Congenital mpox syndrome （clade Ⅰ） in stillborn fetus after placental infection and intrauterine transmission, Democratic Republic of the Congo, 2008［J］. Emerg Infect Dis, 2023,29（11）:2198⁃2022. doi: 10.3201/eid2911.230606.
［15］	Deb S, Mondal R, Sen P, et al. Neuroinflammatory disorders of the central nervous system associated with monkeypox virus: a systematic review and call to action［J］. BMC Med, 2025,23（1）:86. doi: 10.1186/s12916⁃025⁃03921⁃6.
［16］	Maru V, Ghaffar UB, Rawat A, et al. Clinical and epidemiological interventions for monkeypox management in children: a systematic review［J］. Cureus, 2023,15（5）:e38521. doi: 10.7759/cureus.38521.
［17］	Rao AK, Schulte J, Chen TH, et al. Monkeypox in a traveler returning from Nigeria ⁃ Dallas, Texas, July 2021［J］. MMWR Morb Mortal Wkly Rep, 2022,71（14）:509⁃516. doi: 10.15585/mmwr.mm7114a1.
［18］	Rizk Y, Lippi G, Henry BM, et al. Update on mpox management: epidemiology, vaccines and therapeutics, and regulatory changes［J］. Drugs, 2025,85（1）:1⁃9. doi: 10.1007/s40265⁃024⁃02117⁃1.
［19］	Nyame J, Punniyakotti S, Khera K, et al. Challenges in the treatment and prevention of monkeypox infection; a comprehensive review［J］. Acta Trop, 2023,245:106960. doi: 10.1016/j.actatropica. 2023.106960.
［20］	Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK［J］. Lancet Infect Dis, 2022,22（8）:1153⁃1162. doi: 10.1016/S1473⁃3099（22）00228⁃6.
［21］	World Health Organization. Clinical management of acute diarrhoea: WHO/UNICEF joint statement［EB/OL］. （2004⁃12⁃08）［2025⁃03⁃25］. https://www.who.int/publications/i/item/WHO_ FCH_CAH_04.7.
［22］	Bhutta ZA, Das JK, Rizvi A, et al. Evidence⁃based interventions for improvement of maternal and child nutrition: what can be done and at what cost?［J］. Lancet, 2013,382（9890）:452⁃477. doi: 10.1016/S0140⁃6736（13）60996⁃4.
［23］	van Nispen C, Reffett T, Long B, et al. Diagnosis and management of monkeypox: a review for the emergency clinician［J］. Ann Emerg Med, 2023,81（1）:20⁃30. doi: 10.1016/j.annemergmed.2022.07.014.
［24］	Frey SE, Wald A, Edupuganti S, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara （MVA） formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia⁃naïve subjects［J］. Vaccine, 2015,33（39）:5225⁃5234. doi: 10.1016/j.vaccine.2015.06.075.
［25］	Dashraath P, Nielsen⁃Saines K, Rimoin A, et al. Monkeypox in pregnancy: virology, clinical presentation, and obstetric management［J］. Am J Obstet Gynecol, 2022,227（6）:849⁃861. doi: 10.1016/j.ajog.2022.08.017.
［26］	Centers for Disease Control and Prevention. Clinical considerations for monkeypox in children and adolescents［EB/OL］. （2022⁃07⁃26）［2025⁃07⁃20］. https://www.cdc.gov/poxvirus/ monkeypox/clinicians/pediatric.html.

[1]	徐中奕邢小雪董雅琦张成锋项蕾红. 上海市某三甲医院黄褐斑患者254例临床特征及疗效的回顾性分析[J]. 中华皮肤科杂志, 2025, 58(9): 808-815.
[2]	姜子琪钟菊丹陈廷巧陈瑾. 黄褐斑发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(9): 868-872.
[3]	钟洁敏李薇张淑娟杨艳薛如君李欣怡柯娅楠陈晓吟陈荃. 纳米微针与超声波导入氨甲环酸治疗黄褐斑的疗效与安全性比较：一项随机对照研究[J]. 中华皮肤科杂志, 2025, 58(9): 829-833.
[4]	朱婷婷, 李蔚然潘召兵刘昊唐先发朱才红黄鹤群段大威张若晨陈小建汪洋薛倩张菊锐杨丽婧张学军, 黄贺, 张博, . 巴瑞替尼联合芦可替尼乳膏治疗6例进展期非节段型白癜风患者的疗效观察[J]. 中华皮肤科杂志, 2025, 58(9): 856-859.
[5]	姜倩胡彬陈瑶陈柳青. 儿童面部获得性色素沉着斑131例临床及影像学特征回顾分析[J]. 中华皮肤科杂志, 2025, 58(9): 843-847.
[6]	戴叶芹宋秀祖. 毛囊及毛囊细胞移植在白癜风治疗中的应用进展[J]. 中华皮肤科杂志, 2025, 58(9): 882-885.
[7]	周妙妮盛安琪傅丽芳金嵘许文尉晓冬许爱娥. 茶多酚抗氧化凝胶联合窄谱中波紫外线治疗白癜风的疗效及安全性单中心随机对照试验[J]. 中华皮肤科杂志, 2025, 58(9): 834-838.
[8]	罗帅寒天龙海陆前进. 2024年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2025, 58(8): 777-780.
[9]	中国医师协会皮肤科医师分会痤疮学组中国研究型医院学会皮肤科学专业委员会中国中西医结合学会皮肤性病专业委员会痤疮学组. [开放获取] 寻常痤疮临床严重度分级及疗效评价中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 709-714.
[10]	薛珂陈佳李斌. 系统性红斑狼疮靶向治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(8): 781-784.
[11]	陆前进曹淑梅蒋娇. 红斑狼疮研究的现状与挑战[J]. 中华皮肤科杂志, 2025, 58(8): 715-728.
[12]	柏琪朱明芳邬清婷姬孝天杨慧怡马莉苹周佳欣. 青藤碱对DNCB诱导的特应性皮炎样模型小鼠皮损改善的作用研究[J]. 中华皮肤科杂志, 2025, 58(8): 759-766.
[13]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 局限性硬皮病诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 699-708.
[14]	李翔倩张建中周城. 系统小分子药物和生物制剂治疗斑秃的临床研究进展[J]. 中华皮肤科杂志, 2025, 58(7): 646-649.
[15]	林尽染梁晓进刘庆梅吴文育. 雄激素性秃发与代谢综合征的关联：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2025, 58(7): 591-594.

[开放获取] 关注儿童猴痘易感性的现状、挑战与应对

Focusing on the status, challenges and countermeasures of mpox susceptibility in children

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

Metrics

本文评价

推荐阅读 10